Table 1 Clinicopathological characteristics of patient samples and expression of FLOT2 in breast cancer patients
From: Flotillin-2 is associated with breast cancer progression and poor survival outcomes
Number of cases (%) | |
|---|---|
Sex | |
Male | 0(0.0) |
Female | 171(100.0) |
Age (years) | |
≥47 | 85(49.7) |
<47 | 86(50.3) |
Clinical stage | |
I | 21(12.3) |
II | 92(53.8) |
III | 46(26.9) |
IV | 12(7.0) |
T classification | |
T1 | 35(20.5) |
T2 | 89(52.0) |
T3 | 35(20.5) |
T4 | 12(7.0) |
N classification | |
N0 | 70(40.9) |
N1 | 65(38.0) |
N2 | 27(15.8) |
N3 | 9(5.3) |
M classification | |
No | 159(93.0) |
Yes | 12(7.0) |
Vital status (at follow-up) | |
alive | 113(66.1) |
Dead | 58(33.9) |
Histological differentiation | |
Well | 9(5.3) |
Moderate | 113(66.1) |
Poor | 49(28.7) |
Expression of FLOT2 | |
Low expression | 89(52.0) |
High expression | 82(48.0) |
Expression of ER | |
0 | 77(45.0) |
1 | 82(48.0) |
2 | 8(4.73) |
3 | 4(2.3) |
Expression of PR | |
0 | 71(41.5) |
1 | 80(46.8) |
2 | 16(9.4) |
3 | 3(1.8) |
4 | 1(0.6) |
Expression of ErbB-2 | |
0 | 42(24.6) |
1 | 52(30.4) |
2 | 38(22.2) |
3 | 30(17.5) |